Abstract:Abstract Objective: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. T cells are very important in the body's anti-tumor process. However, in HCC, T cell exhaustion not only makes it difficult to implement CAR-T therapy, but also reduces the body's anti-tumor ability or even promotes tumor development. Therefore, it is urgent to explore the relationship between positive regulators of T cells proliferation and HCC. Methods: HCC transcriptome and clinical data were collected from TCGA and ICGC databases. Differentially expressed T-cell positive regulators in the TCGA dataset were analyzed using the R software "limma" package. Univariate COX and Least Absolute Value Convergence and Selection Operator (LASSO) regression analysis established a T cell positive regulator prognostic model, and further combined the risk score with clinicopathological features to construct a nomogram. Single-gene enrichment analysis (ssGSEA) was performed using the R software "gva" package to compare the proportion of immune cells between high and low score groups, and gene set variation (GSVA) to identify significantly enriched signaling pathways in high and low score groups. The "pRRophetic" R software package analyzes the susceptibility of patients with high and low scores to chemotherapy. Further, GO and KEGG pathway enrichment analysis was performed on the differential genes in the high and low score groups, and the "cytoHubba" software was used to find the key differential genes in the high and low score groups.Results: A total of 33 positive regulators of T cell proliferation were identified, and 617 HCC patients were included in the analysis. Among them, 23 T cell positive regulators were significantly differentially expressed in HCC (P<0.05). Patients with high scores in the TCGA dataset had poorer prognosis than those with lower scores, and the results were consistent with the validation results in the ICGC dataset (P<0.05). The levels of antigen-presenting cells, major histocompatibility complex-I, chemokine receptors and immune checkpoints in the high-scoring group were significantly increased (P<0.05). The IC50 values of 5-FU, doxorubicin and mitomycin were significantly lower in the high score group (P<0.05). The highly expressed genes in the high score group were mainly enriched in signaling pathways such as RNA degradation, cell cycle, mismatch repair, and DNA replication, and the highly expressed genes in the low score group were mainly enriched in metabolism-related pathways. The top three key differential genes in the high and low risk groups were CDK1, KIF11, and TOP2A. The prognosis of HCC patients with high expression of CDK1 and low expression was significantly worse (P<0.05), and it was related to clinical stage.Conclusion: The positive regulators of T cell proliferation are significantly differentially expressed in HCC, and the overexpression of related genes brings hope for the application of CAR-T therapy in HCC. The prognostic model of T cell positive regulators promotes the understanding of the characteristics of HCC tumor immune microenvironment infiltration and drug sensitivity, and provides a theoretical basis for the clinical treatment of HCC.

ATG10 Overexpression is Related to the Dismal Prognosis and Promotes the Growth and Migration of Hepatocellular Carcinoma Cells Via Cyclin B1/CDK1 and CDK2

Higher expression of cell division cycle-associated protein 5 predicts poorer survival outcomes in hepatocellular carcinoma

Increased Expression of Autophagy‐related Gene 5 Indicates Poor Prognosis in Patients with Hepatocellular Carcinoma

Autophagy-related Genes Prognosis Signature As Potential Predictive Markers for Immunotherapy in Hepatocellular Carcinoma

ATG4 Promotes Cell Proliferation, Migration and Invasion in HCC and Predicts a Poor Prognosis.

Upregulated TUBG1 expression is correlated with poor prognosis in hepatocellular carcinoma

RAB10 Overexpression Promotes Tumor Growth and Indicates Poor Prognosis of Hepatocellular Carcinoma.

Rpn10 promotes tumor progression by regulating hypoxia-inducible factor 1 alpha through the PTEN/Akt signaling pathway in hepatocellular carcinoma.

EXOSC10 is a novel hepatocellular carcinoma prognostic biomarker: a comprehensive bioinformatics analysis and experiment verification

ATG101-related signature predicts prognosis and therapeutic option in hepatocellular carcinoma

High Expression of Gfat1 Predicts Unfavorable Prognosis in Patients with Hepatocellular Carcinoma

BTBD10 is a Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma.

High Tgf-Beta 1 Expression Predicts Poor Disease Prognosis In Hepatocellular Carcinoma Patients

Identification of an Autophagy-Related Gene Signature Predicting Overall Survival for Hepatocellular Carcinoma.

High Expression of Thymosin Beta 10 Predicts Poor Prognosis for Hepatocellular Carcinoma after Hepatectomy

Characterization of positively regulate T cell proliferation-related genes in hepatocellular cancer to guide clinical therapy

High Expression of TGF-β1 Contributes to Hepatocellular Carcinoma Prognosis Via Regulating Tumor Immunity.

High Expression of N-acetyltransferase 10: a Novel Independent Prognostic Marker of Worse Outcome in Patients with Hepatocellular Carcinoma.

Bioinformatics Analysis Using ATAC-seq and RNA-seq for the Identification of 15 Gene Signatures Associated With the Prediction of Prognosis in Hepatocellular Carcinoma

Integrated Bioinformatics Analysis of the Clinical Value and Biological Function of ATAD2 in Hepatocellular Carcinoma

An Autophagy-Related Prognostic Signature and Verification that ATIC Inhibits Autophagy Through the AMPK/mTOR Pathway in Hepatocellular Carcinoma